Telomir Pharmaceuticals, Inc. (TELO) intrinsic value & 10-year financials
Telomir Pharmaceuticals, Inc. (TELO) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.05
- Market cap
- $33.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -503.6%
- Free cash flow (FY2025)
- —
TELO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$10.4M | -$0.33 | — | — | -317.6% |
| FY2024 | — | -$16.5M | $0.56 | — | — | -810.2% |
| FY2023 | — | -$13.1M | -$0.45 | — | — | -1045.4% |
| FY2022 | — | -$854.1K | -$0.03 | — | — | 158.9% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Telomir Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Telomir Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -5.0% ROIC.
Telomir Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Telomir Pharmaceuticals, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.